The in vitro and in vivo evaluation of tilorone hydrochloride as a platelet aggregation inhibitor.
Tilorone hydrochloride was tested in vitro for inhibition of platelet aggregation in the ADP, collagen, and epinephrine-induced platelet aggregation systems. Tilorone did not significantly inhibit the first phase of platelet aggregation induced by ADP, but was a very potent inhibitor of the second phase of platelet aggregation (release reaction) as illustrated by the epinephrine-induced system. When the compound was given to rats by stomach tube at 100 mg/kg for 2 doses, 24 h apart and blood taken 24 h after the second dose, an inhibition of collagen-induced platelet aggregation was found. This result is interpreted as inhibiting the release reaction and second phase platelet aggregation.
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D003094:Collagen / Q000494:pharmacology; D003864:Depression, Chemical; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D005449:Fluorenes / Q000494:pharmacology*; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D051381:Rats; D013994:Tilorone / Q000494:pharmacology*
D005449:Fluorenes; D000244:Adenosine Diphosphate; D003094:Collagen; D013994:Tilorone; D004837:Epinephrine